INTERIM REPORT

2021

Key Figures

KEY FIGURES HAEMATO AG

GROUP KEY FIGURES (IFRS) IN EUR

Consolidated Profit and Loss Account

01.01. - 30.06.2021

01.01. - 30.06.2020

Sales revenue

151.525

115.808

EBITDA

7.986

2.066

EBIT

7.230

1.230

Net profit for the period

7.038

-2.820

Consolidated balance sheet

30.06.2021

31.12.2020

Short-term assets

82.730

118.977

Long-term assets

104.767

50.081

Equity

147.991

125.480

Liabilities

39.507

43.578

Balance sheet total

187.498

169.058

Equity ratio

78,9%

74,2%

THE SHARE

Class of shares

Share capital

Number of shares as of 31.12.

WKN / ISIN

Ticker symbol

Stock exchanges

Stock exchange listing

Market segment

First trading day

Designated Sponsor, Listing Partner

Specialist

Coverage

Market capitalisation

as of 30.06.2021

as of 31.12.2020

Bearer shares

Bearer shares

EUR 5,229,307

EUR 4,753,916

5,229,307

4,753,916

A289VV / DE000A289VV1

HAEK

Xetra, Frankfurt, Stuttgart, Hamburg, Berlin, München, Tradegate, Düsseldorf

Frankfurter Wertpapierbörse

Entry Standard (Open Market)

05.12.2005

ICF Kursmakler AG

ODDO SEYDLER BANK AG

GBC AG, First Berlin Equity Research GmbH, Warburg Research

EUR 140,67 million (zum 30.06.2021 - Xetra)

2

Key Figures

XETRA

SHARE PERFORMANCE

HAEMATO AG

as of

30.06.2021

(Xetra)

EUR 26.90

40.00 €

35.00 €

30.00 €

28.50 €

25.00 €

20.00 €

15.00 €

10.00 €

01.2020

03.2020

05.2020

07.2020

09.2020

11.2020

01.2021

03.2021

05.2021

3

KEY FACTS

2

Key target markets (DE, AT)

635,000

Packages sold in 2020

1,200

Drug licences

7,100

Regular customers

Suppliers from

22European countries 16

Years of experience (since 2005)

147 Employees

*without mini jobbers/ interns

4,200m2

Total area at

Schönefeld site

4

CONTENT OF THE INTERIM REPORT 2021

1.

COMPANY PROFILE

06

2.

LETTER TO THE SHAREHOLDERS

08

3.

GROUP INTERIM MANAGEMENT REPORT

10

3.1

Economic environment

11

3.1.1

Overall economy

11

3.1.2

Pharmaceutical market

13

3.2

Economic situation

15

3.2.1

Net assets, financial position and earnings

15

situation

3.3

Outlook

16

4.

GROUP INTERIM CONSOLIDATED FINANCIAL

19

STATEMENTS

4.1

Consolidated Balance Sheet - Assets

20

4.2

Consolidated balance sheet - Liabilities

21

4.3

Consolidated Profit and Loss Statement

22

4.4

Consolidated equity Change Account

23

4.5

Consolidated Cash Flow Statement

24

5.

CONDENSED NOTES

25

5.1

General information

26

5.2

Accounting principles

26

5.3

Scope of consolidation

26

5.4

Selected notes to the consolidated

27

balance sheet

5.5

Contingent liabilities

29

5.6

Significant events after June 30, 2021

29

6.

FURTHER INFORMATION

30

6.1

The share

31

6.2

Financial calendar

31

6.3

Glossary

32

6.4

Sources

33

6.5

Imprint

34

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Haemato AG published this content on 31 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 August 2021 06:41:06 UTC.